Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: This meta-analysis evaluates efficacy and safety of anti-reflux mucosal interventions (ARMIs) for gastroesophageal reflux disease (GERD), and comparative effectiveness against traditional interventions.
Methods: A systematic search identified 37 studies (11 comparative and 26 single-arm studies) evaluating ARMIs. Outcomes included GERD symptom scores (GERD-Q, GERD-HRQL), DeMeester score, acid exposure time (AET), complete cessation of proton-pump inhibitor (PPI) therapy, and adverse events (AEs). Random-effects models pooled standardized mean differences (SMDs) and risk ratios (RRs). Subgroup analyses compared techniques (endoscopic mucosal resection [EMR], endoscopic submucosal dissection [ESD], anti-reflux mucosal ablation [ARMA]).
Results: Technical success was 100%, with a mean procedure time of 42.09 minutes. ARMIs significantly reduced the proportion of patients using PPI (RR=2.22-3.06; <3-24 months; P≤0.001) and improved GERD-Q, GERD-HRQL, and DeMeester scores through 36 months (P<0.05). AET decreased at 3-6 months (P<0.001). Overall AEs occurred in 13% of cases (bleeding: 3%; stricture: 8%; dysphagia: 8%). Subgroup analyses demonstrated efficacy across EMR, ESD, and ARMA subtypes (P<0.05), though AE rates differed. Compared to LNF, ARMIs showed similar symptom relief (P>0.05), shorter procedures (P<0.001), and lower dysphagia (X% vs. Y%; P=0.01). Versus Stretta, ARMIs had similar PPI discontinuation rates (P=0.258) and GERD-Q improvement (P=0.696).
Discussion: ARMIs offer durable symptom control with reduced PPI dependency. Preliminary comparative data suggest potential efficacy/safety advantages over LNF/Stretta, warranting randomized trials. Technique selection should balance efficacy and AE profiles.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000548198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: This meta-analysis evaluates efficacy and safety of anti-reflux mucosal interventions (ARMIs) for gastroesophageal reflux disease (GERD), and comparative effectiveness against traditional interventions.
Methods: A systematic search identified 37 studies (11 comparative and 26 single-arm studies) evaluating ARMIs. Outcomes included GERD symptom scores (GERD-Q, GERD-HRQL), DeMeester score, acid exposure time (AET), complete cessation of proton-pump inhibitor (PPI) therapy, and adverse events (AEs).
Anti-Reflux Mucosectomy: Our Experience & Thoughts For The Future.
Curr Gastroenterol Rep
July 2025
Department of Surgery, Endeavor Health, Evanston, IL, 60201, USA.
PURPOSE OF REVIEW: Gastroesophageal reflux disease is prevalent and has a complex pathophysiology. Though medications are first line, a significant proportion of patients are refractory to this treatment and require anti-reflux surgery (ARS). Though surgery has proven safe and effective, most patients and referring providers are reluctant.
View Article and Find Full Text PDFIntroduction: Anti-reflux mucosectomy (ARMS) and anti-reflux mucosal ablation (ARMA) are novel endoscopic treatments for proton pump inhibitor or potassium-competitive acid blocker-refractory gastroesophageal reflux disease. These procedures induce scarring of the artificial ulcer at the gastric cardia, which tightens the enlarged cardiac opening. However, we encountered patients with unresolved symptoms due to insufficient cardiac shrinkage despite multiple ARMS/ARMA treatments.
View Article and Find Full Text PDFEndoscopic anti-reflux mucosal resection for patients with gastroesophageal reflux disease: Clinical efficacy and impact on gut microbiota.
World J Gastrointest Surg
June 2025
Second Department of Gastrointestinal Disease Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China.
Background: In recent years, endoscopic anti-reflux mucosal resection (ARMS) has demonstrated benefits, including good efficacy, ease of operation, low cost, and fewer complications; however, it is still in the exploratory stage.
Aim: To evaluate the clinical efficacy of ARMS in patients with gastroesophageal reflux disease (GERD) and its effects on the gut microbiota.
Methods: This single-center, retrospective, self-controlled study included 80 patients with GERD.
Efficacy and safety of anti-reflux mucosal ablation therapy at 12 months.
Indian J Gastroenterol
June 2025
Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, 500 082, India.
Background And Objectives: Anti-reflux mucosal ablation (ARMA) is a minimally invasive therapy for patients with proton pump inhibitor (PPI) controlled gastro-esophageal reflux disease (GERD). This study evaluated the safety and efficacy of ARMA over 12 months.
Methods: This single-center prospective study included PPI-dependent GERD patients (acid exposure time [AET] > 6% or AET > 4.